Publications by authors named "Katharina Eva Ruppel"
Chimeric antigen receptor (CAR) T cell therapies have demonstrated significant successes in treating cancer. Currently, there are six approved CAR T cell products available on the market that target different malignancies of the B cell lineage. However, to overcome the limitations of CAR T cell therapies, other immune cells are being investigated for CAR-based cell therapies.
View Article and Find Full Text PDFArticle Synopsis
- Allogeneic cell therapies, particularly those using NK cells and macrophages, face challenges in genetic modification due to inefficiencies in current viral vector techniques.
- The study introduces a new lentiviral pseudotype using the Koala Retrovirus envelope, which efficiently transduces freshly isolated human NK cells and monocytes with up to 80% gene expression without compromising cell functionality.
- This innovation streamlines the production of cell-based therapeutics, making it quicker and less resource-intensive, which could lead to faster patient access to effective cancer treatments.
Cancer immunotherapies utilize the capabilities of the immune system to efficiently target malignant cells. In recent years, chimeric antigen receptor (CAR) equipped T cells showed promising results against B cell lymphomas. Autologous CAR-T cells require patient-specific manufacturing and thus extensive production facilities, resulting in high priced therapies.
View Article and Find Full Text PDF